Draw/line
Home / Compare / BPC-157 vs TB-500

BPC-157 vs TB-500

Two unapproved peptides that are often sold together for injury recovery. Here is what each one is, where they stand with FDA after the July 2026 advisory vote, and how thin the evidence is.

Side-by-side facts · No recommendation · Reviewed

BPC-157TB-500Same for both

BPC-157TB-500
What it isSynthetic peptideSynthetic fragment of thymosin beta-4
FDA statusBothNot approved for any use
July 2026 advisory voteNarrowly recommended for the compounding list (ulcerative colitis)Narrowly recommended for the compounding list (wound healing)
Human evidenceA few dozen people in published studiesNo published human trials of TB-500 itself
SportBothBanned at all times (WADA)

What the advisory vote means

In July 2026 an FDA advisory committee narrowly recommended adding both to the list of substances pharmacies may compound. The vote is advisory. It is not FDA approval, and nothing changes legally until FDA finishes rulemaking.

The evidence

BPC-157 research is almost entirely animal and laboratory work. Published human data cover only a few dozen people.

For TB-500 there are no published human trials. FDA has pointed out that human studies of thymosin beta-4, the larger natural protein, are not evidence for the TB-500 fragment.

Blends and sourcing

The two are often sold together in one vial. Products sold online as "research use only" have no assurance of identity, strength or sterility, and a blend makes it harder still to know what is in the vial.

Questions

Are BPC-157 and TB-500 FDA approved?

No. Neither is approved for any use. An FDA advisory committee vote in July 2026 is advisory only.

Can you mix BPC-157 and TB-500 in one syringe?

This site does not advise on combining or using unapproved compounds. The full calculator can do the arithmetic for a blend vial that already contains both.

Which compound, if any, suits a person is a decision for them and a licensed prescriber. This page compares published facts and does not recommend either.

Sources: AJMC: FDA panel backs 6 peptides for compounding; Pharmacy Times: what the peptide vote changes; Black Health: what the FDA peptide vote changed; AJMC: FDA panel backs 6 peptides for compounding; Black Health: what the FDA peptide vote changed; Worst Pills, Best Pills: unapproved peptides.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.